Treatment patterns and outcomes of immunotherapy in extensive-stage small-cell lung cancer based on real-world practice.

ABSTRACT:

Background

The application of immune checkpoint inhibitors (ICIs) represents a breakthrough in the current landscape for the treatment of extensive-stage small-cell lung cancer (ES-SCLC), but the real-world outcome is limited. This study aimed to investigate the treatment options and efficacy evaluation of first-line, second-line, and subsequent-line immunotherapy in routine practice.

Methods

A retrospective analysis of ES-SCLC patients treated with ICIs was conducted between May 2016 and September 2021. Objective response rate, disease control rate, progression-free survival (PFS) and overall survival were assessed between groups to explore the value of ICIs at different treatment time periods. PFS1 and PFS2 were defined as the duration from initial therapy to disease progr

SUBMITTER: Yang Y 

PROVIDER: S-EPMC9715773 | biostudies-literature | 2022 Dec

REPOSITORIES: biostudies-literature